arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive Leaguearthyper-1304Research ArticleСтатьиArticlesВозрастание резистентности к ритуксимабу в комбинации с полихимиотерапией при рецидивах индолентных лимфом. Обзор литературы и собственный опытАлексееваЮ. А.noemail@neicon.ruВабищевичР. И.noemail@neicon.ruГорюноваЕ. Н.noemail@neicon.ruГиршоваЛ. Л.noemail@neicon.ruПетровА. В.noemail@neicon.ruМедведеваН. В.noemail@neicon.ruЗарицкийА. Ю.noemail@neicon.ruГУЗ Городская больница № 31Россия200828022008141-S2108110Copyright © Алексеева Ю.А., Вабищевич Р.И., Горюнова Е.Н., Гиршова Л.Л., Петров А.В., Медведева Н.В., Зарицкий А.Ю., 20082008Алексеева Ю.А., Вабищевич Р.И., Горюнова Е.Н., Гиршова Л.Л., Петров А.В., Медведева Н.В., Зарицкий А.Ю.Алексеева Ю.А., Вабищевич Р.И., Горюнова Е.Н., Гиршова Л.Л., Петров А.В., Медведева Н.В., Зарицкий А.Ю.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1304

Пациенты с индолентными неходжкинскими лимфомами исходно чувствительны к комбинации химиотерапии и ритуксимаба. В рецидиве же ответ на лечение снижается до 50 %. В статье обсуждаются возможные механизмы резистентности к ритуксимабу.

неходжкинская лимфомарезистентность к ритуксимабуReferencesArmitage J.O. and Weisenburger DD. (1998). J. Clin. Oncol. 16. 2780-2795.Armitage J.O. and Weisenburger DD. (1998). J. Clin. Oncol. 16. 2780-2795.Ghielmini M., Rufibach K., Salles G. et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group of Clinical Cancer Research (SAKK). Ann Oncol. 2005: doi: 10.1093.Ghielmini M., Rufibach K., Salles G. et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group of Clinical Cancer Research (SAKK). Ann Oncol. 2005: doi: 10.1093.McLaughlin P., Grillo-Lopez A.J., Link U.K., Levy R. Czuczman M.S. Williams M.E., Heyman M.R., Henee-Bruekler I., White C.A., Cahanillas L., Jain V.I., In A.D., Lister J., Wey K., Shen D. and Dallaire B.K. (1998). / Clin. Oncol., 8, 2825-2833.McLaughlin P., Grillo-Lopez A.J., Link U.K., Levy R. Czuczman M.S. Williams M.E., Heyman M.R., Henee-Bruekler I., White C.A., Cahanillas L., Jain V.I., In A.D., Lister J., Wey K., Shen D. and Dallaire B.K. (1998). / Clin. Oncol., 8, 2825-2833.Witzig Т.Е., Flinn I.W., Gordon L.I. et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 2002; 20: 3262-3269.Witzig Т.Е., Flinn I.W., Gordon L.I. et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol, 2002; 20: 3262-3269.Harjunpaa A., Wikiund T., Collan J., Janes R., Rosenberg J., Lee D., Gfillo-Lopez A. and Meri S. (2001). Leukemia Lymphoma, 42, 731-738.Harjunpaa A., Wikiund T., Collan J., Janes R., Rosenberg J., Lee D., Gfillo-Lopez A. and Meri S. (2001). Leukemia Lymphoma, 42, 731-738.Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D. and Mellstedt H. (1997). J. Clin. Oncol., 15, 1567-1574.Osterborg A., Dyer M.J., Bunjes D., Pangalis G.A., Bastion Y., Catovsky D. and Mellstedt H. (1997). J. Clin. Oncol., 15, 1567-1574.Jazirehi A.R., Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan. anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005: 24: 2121-2143.Jazirehi A.R., Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan. anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene. 2005: 24: 2121-2143.Nieves Diaz M.D. Eugeny A., Osmanov M.D., Yulia A., Alexeeva M.D. Mikhail Yu., Byakhov M.D., Oleg N., Lipatov M.D., Sergey K., Kravchenko M.D., Ilya S., Zuzgin M.D., Felix T., Garzon M.D., Laurence Elias M.D. and Philippe Solal-Celigny M.D. Safety and Tdleiahiliiy of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory Relapsed Follicular Non I lodgkin Lymphoma. Preliminary Data from the Pearl Study. Blond (ASH Annual Meeting Abstracts) 2005 106: Abstract 4783.Nieves Diaz M.D. Eugeny A., Osmanov M.D., Yulia A., Alexeeva M.D. Mikhail Yu., Byakhov M.D., Oleg N., Lipatov M.D., Sergey K., Kravchenko M.D., Ilya S., Zuzgin M.D., Felix T., Garzon M.D., Laurence Elias M.D. and Philippe Solal-Celigny M.D. Safety and Tdleiahiliiy of the Combination of Interleukin-2 (rIL-2) and Rituximab in Patients with Refractory Relapsed Follicular Non I lodgkin Lymphoma. Preliminary Data from the Pearl Study. Blond (ASH Annual Meeting Abstracts) 2005 106: Abstract 4783.Jolay J., Zaffaroni L., Vaccari Т. еt al. Biologic response ot В lymphoma cells to anti-CD59 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000: 95: 3900-3908.Jolay J., Zaffaroni L., Vaccari Т. еt al. Biologic response ot В lymphoma cells to anti-CD59 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000: 95: 3900-3908.

The authors declare that there are no conflicts of interest present.